Minerva Surgical Inc UTRS Stock Analysis
- PINK
- Stock
- Market closed · opens Monday 9:30 AM ET
$0.00
Last close · Previous close $0.00
Closing prices across missing sessions after Jan 13 differ by the size of move a stock split causes. Until Tiingo publishes the missing split-adjusted prices, the Nov 6 price isn’t compared with earlier prices.
- Market cap
- $888.00As of Nov 6, 2026
- P/E ratio
- PausedOn last 12 months’ EPS
See the note under the price. - Diluted EPS
- PausedLast 12 months
See the note under the price. - Dividend yield
- NoneLast 12 months
Price chart
$0.00Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$0.00Nov 5
- Volume0.00Nov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume20.00Last 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.00 to $0.00
The lowest and highest trades over the past 52 weeks. The Nov 6 close isn’t marked: the range doesn’t yet reflect the stock split that the Nov 6 close suggests.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Returns are paused: earlier prices don’t yet reflect the stock split that the Nov 6 close suggests. See the note under the price.
All-time high
$195.60
Closing high on .
Split-adjusted daily closes since Oct 22, 2021.
Stock splits
1
1-for-20 on . Share counts adjust after each split.
The Nov 6 close suggests a stock split that the price history doesn’t include yet. See the note under the price.
Valuation
Price-based measures are paused: per-share results don’t yet reflect the stock split that the Nov 6 close suggests. See the note under the price. Market cap and enterprise value are as of Nov 6, 2026. Tap a metric to see how it’s calculated. Per-share results and the measures based on them are paused. See the note under the price.
Price-to-earnings (P/E)
Paused
Other valuation measures
- Price-to-salesPausedSee the split note
- Price-to-bookPausedBook value as of Sep 30, 2023
See the note under the price. - EV/EBITDAPausedSee the split note
- PEG ratioPausedLast 12 months’ EPS growth
See the note under the price. - Free cash flow yieldPausedSee the split note
- $32.35MAs of Nov 6, 2026
What it would cost to buy the whole business: the market cap on Nov 6, 2026, plus debt, minus cash and short-term investments from the Sep 30, 2023 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own UTRS DCF in Excel. Value Minerva Surgical with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q3 FY23, the quarter ended Sep 30, 2023. “Last 12 months” means the four quarters from Oct 1, 2022 to Sep 30, 2023, and balance-sheet figures are as of Sep 30, 2023.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $51.69Mup 3.1%
- Net income
- −$33.45M
- Diluted EPS
- PausedSee the note under the price.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q4 FY21 (Dec 31, 2021) | $13.65M | $10.81M | Paused See the note under the price. |
| Q1 FY22 (Mar 31, 2022) | $10.94M | −$10.93M | Paused See the note under the price. |
| Q2 FY22 (Jun 30, 2022) | $12.97M | −$5.61M | Paused See the note under the price. |
| Q3 FY22 (Sep 30, 2022) | $12.59M | −$11.33M | Paused See the note under the price. |
| Q4 FY22 (Dec 31, 2022) | $13.80M | −$6.25M | Paused See the note under the price. |
| Q1 FY23 (Mar 31, 2023) | $12.53M | −$11.34M | Paused See the note under the price. |
| Q2 FY23 (Jun 30, 2023) | $13.39M | −$8.68M | Paused See the note under the price. |
| Q3 FY23 (Sep 30, 2023) | $11.97M | −$7.18M | Paused See the note under the price. |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY20 (Dec 31, 2020) | $37.77M | −$18.26M | Paused See the note under the price. |
| FY21 (Dec 31, 2021) | $52.10M | −$21.46M | Paused See the note under the price. |
| FY22 (Dec 31, 2022) | $50.29M | −$34.11M | Paused See the note under the price. |
Margins
- Gross 54.2%
- Operating −56.6%
- Net −64.7%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$38.79MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$38.73MLast 12 months
- Capital spending$53.00KLast 12 months
- −75.0%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $26.86MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $11.47MAs of Sep 30, 2023
Cash plus short- and long-term marketable securities on the Sep 30, 2023 balance sheet.
- Total debt$43.55MAs of Sep 30, 2023
- Net debt$32.08MAs of Sep 30, 2023
- Book value per sharePausedAs of Sep 30, 2023
See the note under the price. - 1.88As of Sep 30, 2023
Current assets divided by current liabilities on the Sep 30, 2023 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 2.15As of Sep 30, 2023
Total debt divided by shareholders’ equity on the Sep 30, 2023 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 1 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✗Return on assets improved: not passed
- ✗Operating cash flow exceeded net income: not passed
- ✓Long-term debt fell relative to assets: passed
- ✗Current ratio improved: not passed
- ✗Share count didn’t rise: not passed
- ✗Gross margin improved: not passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- −136.4%Last 12 months
Over the last 12 months, Minerva Surgical lost money: its net loss was 136.4% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −43.7%Last 12 months
Over the last 12 months, Minerva Surgical’s net loss was 43.7% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Minerva Surgical Inc
Minerva Surgical is a commercial-stage medical technology company focused on developing, manufacturing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women. The Company has established a broad product line of commercially available, minimally invasive alternatives to hysterectomy, which are designed to address the most common causes of Abnormal Uterine Bleeding (AUB) in most uterine anatomies. The Minerva Surgical solutions can be used in a variety of medical treatment settings and aim to address the drawbacks associated with alternative treatment methods and to preserve the uterus by avoiding unnecessary hysterectomies.
- Sector
- Healthcare
- Industry
- Health Information Services
- Headquarters
- California, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- PINK
- Asset type
- Common stock
- Price history since
UTRS news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
UTRS stock FAQ
What is UTRS stock’s price today?
Minerva Surgical (UTRS) traded at $0.00 at the close on . That price suggests a stock split that earlier prices on this page don’t reflect yet.
What is Minerva Surgical’s market cap?
Minerva Surgical’s market capitalization was about $0.9 thousand on , according to Tiingo’s daily data (how market cap works).
How much revenue does Minerva Surgical make?
Minerva Surgical reported $51.7 million of revenue over the four quarters to , up 3.1% from the twelve months before. In its latest quarter (Q3 FY23, ended ) revenue was $12.0 million, down 4.9% from a year earlier.
Is Minerva Surgical profitable?
Not over the four quarters to . Minerva Surgical reported a net loss of $33.5 million across those four quarters on $51.7 million of revenue.
Does UTRS pay a dividend?
Minerva Surgical hasn’t paid a dividend in the last twelve months.
What is UTRS’s 52-week high and low?
Over the past 52 weeks UTRS has traded as low as $0.00 and as high as $0.00.
What is UTRS’s all-time high?
UTRS’s highest closing price was $195.60 on , adjusted for stock splits.
Has UTRS stock ever split?
Yes, once: 1-for-20 on . The Nov 6 close suggests a stock split that the price history doesn’t include yet.
What sector and industry is Minerva Surgical in?
Minerva Surgical is in the Healthcare sector and the Health Information Services industry, and is headquartered in California, USA.
What exchange does UTRS trade on?
Minerva Surgical trades on the PINK under the ticker symbol UTRS. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.